Comparing the therapeutic efficacy of Terbinafine and Ketoconazole in treatment of Tinea Versicolor

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903194128N1

Enrollment

Registered

2010-09-09

Start date

2007-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinea Versicolor. Infections of the skin and subcutaneous tissue

Interventions

Intervention 1: Ketoconazole group: Ketoconazole 2% once daily for 2 weeks. Intervention 2: Terbinafine group: Terbinafine 1% once daily for 2 weeks.

Treatment - Drugs

Ketoconazole group: Ketoconazole 2% once daily for 2 weeks

Terbinafine group: Terbinafine 1% once daily for 2 weeks

Eligibility

Sex/Gender

All

Age

16 Years to 37 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patient with Tinea Versicoler and positive smear. Exclusion criteria: pregnancy, sensitivity to Ketoconazole and Terbinafihne, receiving antifungoal drugs during 1 month ego, liver disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cilinical improvment. Timepoint: 1 month. Method of measurement: cilinical observation.	—

Secondary

Measure	Time frame
Drug compilications. Timepoint: 2 weak post treatment and monthly intervals for 3 months . Method of measurement: cilinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Majid Rostami

Ardabil University of Medical Sciences

m.rostami@arums+98 45 1224 6687

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026